P
Philipp L. Müller
Researcher at University of Bonn
Publications - 64
Citations - 2523
Philipp L. Müller is an academic researcher from University of Bonn. The author has contributed to research in topics: Macular degeneration & Retinopathy. The author has an hindex of 22, co-authored 59 publications receiving 2103 citations. Previous affiliations of Philipp L. Müller include University of Duisburg-Essen & Moorfields Eye Hospital.
Papers
More filters
Journal ArticleDOI
A therapeutic vaccine for nicotine dependence: preclinical efficacy, and phase I safety and immunogenicity
Patrik Maurer,Gary T. Jennings,Jörg Willers,Franziska Rohner,Ylva Lindman,Kirsten Roubicek,Wolfgang A. Renner,Philipp L. Müller,Martin F. Bachmann +8 more
TL;DR: It is suggested that antibodies induced by NicQb may prevent relapses by sequestering nicotine in the blood of immunized smokers by blocking nicotine from entering the brain by induction of specific antibodies.
Journal ArticleDOI
A Vaccine against Nicotine for Smoking Cessation: A Randomized Controlled Trial
Jacques Cornuz,Susanne Zwahlen,Walter Felix Jungi,Joseph Osterwalder,Karl Klingler,Guy van Melle,Yolande Bangala,Idris Guessous,Philipp L. Müller,Jörg Willers,Patrik Maurer,Martin F. Bachmann,Thomas Cerny +12 more
TL;DR: Subgroup analyses of the per-protocol population suggest that such a vaccination against nicotine can significantly increase continuous abstinence rates in smokers when sufficiently high antibody levels are achieved, which might open a new avenue to the treatment of nicotine addiction.
Journal ArticleDOI
Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study.
Alain Tissot,Patrik Maurer,Juerg Nussberger,Robert Sabat,Thomas Pfister,Stanislav Ignatenko,Hans-Dieter Volk,Hans Stocker,Philipp L. Müller,Gary T. Jennings,Frank Wagner,Martin F. Bachmann +11 more
TL;DR: Immunisation with CYT006-AngQb-a vaccine based on a virus-like particle-that targets angiotensin II to reduce ambulatory blood pressure was associated with no serious adverse events; most observed adverse events were consistent with local or systemic responses similar to those seen with other vaccines.
Journal ArticleDOI
A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity.
Patrice M. Ambühl,Alain Tissot,Alma Fulurija,Patrik Maurer,Juerg Nussberger,Robert Sabat,Vera Nief,Charlotte Schellekens,Katja Sladko,Kirsten Roubicek,Thomas Pfister,Manfred Rettenbacher,Hans-Dieter Volk,Frank Wagner,Philipp L. Müller,Gary T. Jennings,Martin F. Bachmann +16 more
TL;DR: AngQb reduces blood pressure in SHR to levels obtained with an ACE inhibitor, and is immunogenic and well tolerated in humans, Therefore, vaccination against angiotensin II has the potential to become a useful antihypertensive treatment providing long-lasting effects and improving patient compliance.
Journal ArticleDOI
Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial.
Gabriela Senti,Pål Johansen,S Haug,C Bull,C. Gottschaller,Philipp L. Müller,Thomas Pfister,Patrik Maurer,Martin F. Bachmann,Nicole Graf,Thomas M. Kündig +10 more
TL;DR: The phase I/IIa study presented represents the first test of A‐type CpGs in humans and shows that upon association with virus‐like particles (VLP) consisting of the bacteriophage Qβ coat protein, A‐ type CpG ODN can be stabilized and can become an efficient adjuvant in mice.